BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263-271. [PMID: 28412293 DOI: 10.1016/j.jhep.2017.03.039] [Cited by in Crossref: 213] [Cited by in F6Publishing: 191] [Article Influence: 42.6] [Reference Citation Analysis]
Number Citing Articles
1 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
2 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
3 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
4 García Deltoro M, Ricart Olmos C. Hepatitis C virus infection and new treatment strategies. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37 Suppl 1:15-9. [PMID: 31138418 DOI: 10.1016/S0213-005X(19)30177-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Matthew AN, Leidner F, Lockbaum GJ, Henes M, Zephyr J, Hou S, Rao DN, Timm J, Rusere LN, Ragland DA, Paulsen JL, Prachanronarong K, Soumana DI, Nalivaika EA, Kurt Yilmaz N, Ali A, Schiffer CA. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chem Rev 2021;121:3238-70. [PMID: 33410674 DOI: 10.1021/acs.chemrev.0c00648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Valdez-Hernández P, Rodríguez-Aguilar EF, Páez-Zayas VM, Lizárraga-Gómez E, García-Juárez I. [Proposal for a simple scheme of direct-action antivirals for HCV treatment in a low budget public health system]. Salud Publica Mex 2018;60:738-40. [PMID: 30699280 DOI: 10.21149/9492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830 [PMID: 34447228 DOI: 10.3748/wjg.v27.i29.4818] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kosloski MP, Oberoi R, Wang S, Viani RM, Asatryan A, Hu B, Ding B, Qi X, Kim EJ, Mensa F, Kort J, Liu W. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals. J Infect Dis. 2020;221:223-231. [PMID: 31504702 DOI: 10.1093/infdis/jiz439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
11 Abd Alla MDA, Dawood RM, Rashed HAE, Farrag G, Ammar IAE, Mahmoud MMA, Salum GM, Altanbouly AMA, El Meguid MA, Awady MKE. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Arch Virol 2021;166:1071-81. [PMID: 33533976 DOI: 10.1007/s00705-021-04969-4] [Reference Citation Analysis]
12 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
13 Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, Watanabe T, Yoshida O, Tokumoto Y, Mashiba T, Yokota T, Abe M, Michitaka K, Hiasa Y, Joko K. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100. [PMID: 33278003 DOI: 10.1007/s00535-020-01747-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-237. [PMID: 29116550 DOI: 10.1007/s11904-017-0369-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
15 Kosloski MP, Zhao W, Li H, Pugatch D, Asatryan A, Kort J, Mensa FJ, Liu W. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects. Clin Pharmacol Drug Dev 2019;8:779-89. [PMID: 30861340 DOI: 10.1002/cpdd.671] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
16 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Chen J, Chiu Y, Lee P, Tung H, Chiu H, Chien S, Cheng P. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.04.020] [Reference Citation Analysis]
18 Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jabłonowska E, Østergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A; EuroSIDA study group. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. J Acquir Immune Defic Syndr 2021;86:248-57. [PMID: 33079903 DOI: 10.1097/QAI.0000000000002541] [Reference Citation Analysis]
19 Deng H, Guo F, Yu W, Li L, Xia Y, Guan Y, Li J. Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients. Virus Res 2021;302:198453. [PMID: 33991622 DOI: 10.1016/j.virusres.2021.198453] [Reference Citation Analysis]
20 Solomon SS, McFall AM, Lucas GM, Srikrishnan AK, Kumar MS, Anand S, Quinn TC, Celentano DD, Mehta SH. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis. PLoS Med 2017;14:e1002460. [PMID: 29182638 DOI: 10.1371/journal.pmed.1002460] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
21 Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat 2019;26:951-60. [PMID: 30977945 DOI: 10.1111/jvh.13110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 2018;15:180. [PMID: 30466446 DOI: 10.1186/s12985-018-1094-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
23 Calleja JL, Macias J, Forns X, Garcia F, Berenguer M, Garcia Deltoro M, Buti M, Granados R, Carrion JA, Morano L, Fernandez I, Coste P, Pineda JA. Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol 2018;41:597-608. [PMID: 30270150 DOI: 10.1016/j.gastrohep.2018.07.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
24 Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Adv Ther 2018;35:1087-102. [DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
25 Matthew AN, Kurt Yilmaz N, Schiffer CA. Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C InfectionPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry 2018;57:481-2. [PMID: 29192768 DOI: 10.1021/acs.biochem.7b01160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
26 Assoumou SA, Nolen S, Hagan L, Wang J, Eftekhari Yazdi G, Thompson WW, Mayer KH, Puro J, Zhu L, Salomon JA, Linas BP. Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. Am J Med 2020;133:e641-58. [PMID: 32603791 DOI: 10.1016/j.amjmed.2020.05.029] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. J Viral Hepat 2018;25:1078-88. [PMID: 29624809 DOI: 10.1111/jvh.12906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J 2021;18:69. [PMID: 34193156 DOI: 10.1186/s12954-021-00519-y] [Reference Citation Analysis]
29 Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure 2018;26:1360-1372.e5. [PMID: 30146168 DOI: 10.1016/j.str.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
30 Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology 2019;69:2349-63. [PMID: 30693573 DOI: 10.1002/hep.30527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
31 Costa VD, Pellegrini P, Rotman V, Pittella AM, Nunes EP, Lago BV, Lampe E, Mello FCA. Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports. Viruses 2019;11:E1004. [PMID: 31683616 DOI: 10.3390/v11111004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Churkin A, Kriss S, Uziel A, Goyal A, Zakh R, Cotler SJ, Etzion O, Shlomai A, Rotstein HG, Dahari H, Barash D. Machine learning for mathematical models of HCV kinetics during antiviral therapy. Math Biosci 2021;343:108756. [PMID: 34883104 DOI: 10.1016/j.mbs.2021.108756] [Reference Citation Analysis]
33 Takaki S, Imamura M, Yamaguchi S, Fukuhara T, Mori N, Tsuji K, Ohya K, Hayes CN, Aikata H, Chayama K. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol 2020;13:1233-8. [PMID: 32656649 DOI: 10.1007/s12328-020-01182-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. Gut Liver 2021;15:440-50. [PMID: 32839365 DOI: 10.5009/gnl19393] [Reference Citation Analysis]
35 Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85. [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
36 Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. Clin Infect Dis 2018;67:1493-7. [PMID: 30215670 DOI: 10.1093/cid/ciy586] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
37 Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. J Gen Virol 2019;100:1123-31. [PMID: 31199224 DOI: 10.1099/jgv.0.001268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Chen JJ, Lee PL, Chiu HC, Tung HD, Chiu YC, Cheng PN. Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan. J Gastroenterol Hepatol 2020;35:467-72. [PMID: 31445507 DOI: 10.1111/jgh.14845] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
39 Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Li J, Wu DB, Jiang W, Chen XB, Xiao GB, Wang YH, Wang ML, Tao YC, Chen EQ. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study. Medicine (Baltimore) 2020;99:e22726. [PMID: 33120769 DOI: 10.1097/MD.0000000000022726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
42 Wong A, Tsien C, Mansour S, Cooper C. Remaining clinical issues in hepatitis C treatment. CanLivJ 2018;1:66-77. [DOI: 10.3138/canlivj.1.2.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Trooskin S, Jhaveri R. Conversations With the Editors: Hepatitis C Virus-Where are We Now and Where Do We Go From Here? Clin Ther 2020;42:1425-32. [PMID: 32778344 DOI: 10.1016/j.clinthera.2020.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Yang R, Wei L. Profile of the VERSANT HCV genotype 2.0 assay. Expert Rev Mol Diagn 2018;18:995-1004. [PMID: 30372355 DOI: 10.1080/14737159.2018.1541740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Wei B, Ji F, Yeo YH, Ogawa E, Zou B, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018;5:e000207. [PMID: 30002863 DOI: 10.1136/bmjgast-2018-000207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
46 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Gardenier D, Olson MC. Hepatitis C in 2019: Are We There Yet? The Journal for Nurse Practitioners 2019;15:415-419.e1. [DOI: 10.1016/j.nurpra.2018.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Boonma T, Nutho B, Darai N, Rungrotmongkol T, Nunthaboot N. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. J Biomol Struct Dyn 2021;:1-12. [PMID: 33430709 DOI: 10.1080/07391102.2020.1869587] [Reference Citation Analysis]
49 Wilder JM, Muir A. Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opin Pharmacother 2018;19:451-6. [PMID: 29488438 DOI: 10.1080/14656566.2018.1446945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Nguyen T, Valantin MA, Delaugerre C, Amiel C, Netzer E, L'Yavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. J Glob Antimicrob Resist 2021;24:311-5. [PMID: 33540082 DOI: 10.1016/j.jgar.2021.01.012] [Reference Citation Analysis]
51 Kosloski MP, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir. Antimicrob Agents Chemother 2017;61:e00958-17. [PMID: 28807904 DOI: 10.1128/AAC.00958-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
52 Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
53 D'ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology 2019;70:379-87. [DOI: 10.1016/j.jhep.2018.11.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 23.3] [Reference Citation Analysis]
54 Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019;15:73-86. [DOI: 10.1038/s41581-018-0081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
55 Lamb YN. Glecaprevir/Pibrentasvir: First Global Approval. Drugs 2017;77:1797-804. [DOI: 10.1007/s40265-017-0817-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
56 Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. J Viral Hepat 2018;25:1180-8. [DOI: 10.1111/jvh.12917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
57 Kwo PY, Shiffman ML, Bernstein DE. The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. American Journal of Gastroenterology 2018;113:2-4. [DOI: 10.1038/ajg.2017.420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
58 Jhaveri R, Yee LM, Antala S, Murphy M, Grobman WA, Shah SK. Responsible Inclusion of Pregnant Individuals in Eradicating HCV. Hepatology 2021. [PMID: 33743550 DOI: 10.1002/hep.31825] [Reference Citation Analysis]
59 Eckman MH, Woodle ES, Thakar CV, Alloway RR, Sherman KE. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. Am J Kidney Dis 2020;75:857-67. [PMID: 32081494 DOI: 10.1053/j.ajkd.2019.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
60 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
61 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62:pii: e02217-17. [PMID: 29180522 DOI: 10.1128/aac.02217-17:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Mohammed Abdul MK, Snyder HS, Chunduru M, Lee SMK, Satapathy SK. Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure. Curr Treat Options Infect Dis 2020;:1-14. [PMID: 32837340 DOI: 10.1007/s40506-020-00231-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Némoz B, Roger L, Leroy V, Poveda JD, Morand P, Larrat S. Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures. PLoS One 2018;13:e0194396. [PMID: 29566005 DOI: 10.1371/journal.pone.0194396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
64 Zuckerman A, Chastain CA, Naggie S. Retreatment Options Following HCV Direct Acting Antiviral Failure. Curr Treat Options Infect Dis 2017;9:389-402. [PMID: 29242710 DOI: 10.1007/s40506-017-0136-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
65 Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)., Deutsche Gesellschaft für Pathologie e. V. (DGP) und Bundesverband Deutscher Pathologen (BDP)., Deutsche Leberstiftung., Gesellschaft für Virologie e. V. (GfV)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH)., Schweizerische Gesellschaft für Gastroenterologie (SGG)., Deutsche Transplantationsgesellschaft e. V. (DTG)., Deutsche Leberhilfe e. V., Deutsche Gesellschaft für Infektiologie e. V. (DGI)., Deutsche Gesellschaft für Suchtmedizin e. V. (DGS)., Deutsche AIDS-Gesellschaft e. V. (DAIG)., Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ)., Robert Koch-Institut (RKI)., Collaborators:. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Z Gastroenterol 2020;58:1110-31. [PMID: 33197953 DOI: 10.1055/a-1226-0241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int 2020;14:225-38. [PMID: 32128704 DOI: 10.1007/s12072-020-10019-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
67 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
68 Oberoi RK, Zhao W, Rosebraugh M, Mensa F, Wang H, Liu W. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects. Clin Ther 2020;42:1317-29. [PMID: 32622784 DOI: 10.1016/j.clinthera.2020.05.009] [Reference Citation Analysis]
69 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
70 Sochat M, Hermelin D, Chakos D, Farooqui A, Lunt J, Vartanyan A, Poddar N. When the diagnosis is difficult to digest: severe vitamin B12 deficiency secondary to pernicious anemia mimicking life-threatening thrombotic thrombocytopenic purpura. J Hematopathol 2019;12:31-5. [DOI: 10.1007/s12308-019-00340-4] [Reference Citation Analysis]
71 Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. J Viral Hepat 2019;26:1266-75. [PMID: 31278795 DOI: 10.1111/jvh.13170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
73 d'Avigdor WMH, Budzinska MA, Lee M, Lam R, Kench J, Stapelberg M, McLennan SV, Farrell G, George J, McCaughan GW, Tu T, Shackel NA. Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. Sci Rep 2019;9:10596. [PMID: 31332246 DOI: 10.1038/s41598-019-46664-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
74 Dikopoulos N, Backhus J, Dollinger M. [The news in hepatitis C therapy]. MMW Fortschr Med 2017;159:43-52. [PMID: 29086258 DOI: 10.1007/s15006-017-9595-4] [Reference Citation Analysis]
75 AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018;67:1477-92. [PMID: 30215672 DOI: 10.1093/cid/ciy585] [Cited by in Crossref: 277] [Cited by in F6Publishing: 243] [Article Influence: 92.3] [Reference Citation Analysis]
76 Saab S, Kullar R, Amini C, Gounder P. WITHDRAWN: The next frontier: universal hepatitis C virus screening in pregnant women. Am J Obstet Gynecol 2020:S0002-9378(20)30133-2. [PMID: 32044311 DOI: 10.1016/j.ajog.2020.01.058] [Reference Citation Analysis]
77 Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, Aichelburg MC, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterol J 2019;7:507-16. [PMID: 31065368 DOI: 10.1177/2050640619835394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
78 Morgan JR, Kim AY, Naggie S, Linas BP. The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infect Dis 2018;5:ofx267. [PMID: 29354660 DOI: 10.1093/ofid/ofx267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. Int J Biol Macromol 2021;172:524-41. [PMID: 33454328 DOI: 10.1016/j.ijbiomac.2021.01.076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45-51. [PMID: 30393106 DOI: 10.1016/s2468-1253(18)30341-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
81 Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Wörns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis 2019;69:1657-64. [PMID: 30923816 DOI: 10.1093/cid/ciz022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
82 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
83 Klimova EA, Burnevich EZ, Chulanov VP, Gusev DA, Znoyko OO, Batskikh SN, Kizlo SN, Mamonova NA, Tarkhova EP, Krasavina EN, Samsonov MY, Yushchuk ND. [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C]. Ter Arkh 2019;91:67-74. [PMID: 32598756 DOI: 10.26442/00403660.2019.08.000384] [Reference Citation Analysis]
84 Cannon RM, Locke JE, Orandi BJ, Anderson DJ, Davis EG, Mackelaite L, Dave H, Eng M, Jones CM. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index? Transplantation 2020;104:1215-28. [PMID: 31517783 DOI: 10.1097/TP.0000000000002949] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
85 Wu DB, Jiang W, Wang YH, Chen B, Wang ML, Tao YC, Chen EQ, Tang H. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. J Viral Hepat 2019;26:316-22. [PMID: 30380166 DOI: 10.1111/jvh.13033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
86 Mohamed AA, El-Toukhy NER, Said EM, Gabal HMR, AbdelAziz H, Doss W, El-Hanafi H, El Deeb HH, Mahmoud S, Elkadeem M, Shalby HS, Abd-Elsalam S. Hepatitis C Virus: Efficacy of New DAAs Regimens. Infect Disord Drug Targets 2020;20:143-9. [PMID: 30663575 DOI: 10.2174/1871526519666190121114003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
87 Beisel C, Herrmann M, Piecha F, Lampalzer S, Buescher G, Pischke S, Schulze zur Wiesch J. Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110077] [Reference Citation Analysis]
88 Patel EU, Solomon SS, Mcfall AM, Srikrishnan AK, Pradeep A, Nandagopal P, Laeyendecker O, Tobian AAR, Thomas DL, Sulkowski MS, Kumar MS, Mehta SH. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Int J Drug Policy 2018;57:51-60. [PMID: 29679811 DOI: 10.1016/j.drugpo.2018.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
89 Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Ortiz GA, Trivedi HD, Nader C. Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. Hemodial Int 2018;22 Suppl 1:S22-35. [PMID: 29694720 DOI: 10.1111/hdi.12648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
91 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
92 Kosloski MP, Zhao W, Marbury TC, Preston RA, Collins MG, Pugatch D, Mensa F, Kort J, Liu W. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects. Antimicrob Agents Chemother 2018;62:e01990-17. [PMID: 29263061 DOI: 10.1128/AAC.01990-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
93 Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol 2022. [PMID: 35031857 DOI: 10.1007/s00535-021-01837-5] [Reference Citation Analysis]
94 Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, Cohen DE, Gane E. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). J Viral Hepat. 2018;25:118-125. [PMID: 28833938 DOI: 10.1111/jvh.12782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
95 Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother 2017;18:1235-42. [PMID: 28644739 DOI: 10.1080/14656566.2017.1346609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
96 Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307. [PMID: 29672891 DOI: 10.1002/hep.30046] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
97 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
98 Carrion AF, Martin P. Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother 2018;19:413-9. [PMID: 29465262 DOI: 10.1080/14656566.2018.1444030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
99 Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, Seike M, Takei Y, Kato K, Alves K, Burroughs M, Redman R, Pugatch DL, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557-565. [PMID: 28948366 DOI: 10.1007/s00535-017-1391-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 16.2] [Reference Citation Analysis]
100 Flamm S, Reddy KR, Zadeikis N, Hassanein T, Bacon BR, Maieron A, Zeuzem S, Bourliere M, Calleja JL, Kosloski MP, Oberoi RK, Lin CW, Yu Y, Lovell S, Semizarov D, Mensa FJ. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Clin Gastroenterol Hepatol 2019;17:527-535.e6. [PMID: 30012435 DOI: 10.1016/j.cgh.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
101 Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clin Gastroenterol Hepatol 2019;17:930-939.e9. [PMID: 30201597 DOI: 10.1016/j.cgh.2018.08.080] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
102 Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions. Viruses 2019;11:E148. [PMID: 30754682 DOI: 10.3390/v11020148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
103 Lagging M, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J; ; for the Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infect Dis (Lond) 2018;50:569-83. [PMID: 29495923 DOI: 10.1080/23744235.2018.1445281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
104 Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real‐world cohort study. Hepatol Res 2019;49:617-26. [DOI: 10.1111/hepr.13328] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
105 Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. J Viral Hepat 2021;28:558-68. [PMID: 33306247 DOI: 10.1111/jvh.13454] [Reference Citation Analysis]
106 Ferenci P. New anti-HCV drug combinations: who will benefit? Lancet Infect Dis 2017;17:1008-9. [PMID: 28818545 DOI: 10.1016/S1473-3099(17)30486-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
107 Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, Zadeikis N, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019;14:e0208506. [PMID: 30601818 DOI: 10.1371/journal.pone.0208506] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
108 Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'rear JJ, Naeger LK. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018;67:2430-48. [DOI: 10.1002/hep.29693] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
109 Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69:293-300. [PMID: 29551706 DOI: 10.1016/j.jhep.2018.03.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 21.8] [Reference Citation Analysis]
110 Chris Krueger A, Chen HJ, Randolph JT, Brown BS, Halvorsen GT, Heyman HR, Li T, Marvin CC, Shanley JP, Voight EA, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin ML, Krishnan P, Henry RF, Wagner R, DeGoey DA. Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus. Bioorg Med Chem 2020;28:115208. [PMID: 31740203 DOI: 10.1016/j.bmc.2019.115208] [Reference Citation Analysis]
111 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
112 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
113 Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, Cela M, Copetti M, Losappio R. SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS One 2019;14:e0215783. [PMID: 31091254 DOI: 10.1371/journal.pone.0215783] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
114 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
115 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
116 Shen C, Fan H, Ge Z, Cai W, Shao J, Dong C, Xue H, Fu Z, Li J, Zhang Y, Yue M. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med (Lausanne) 2020;7:592472. [PMID: 33425940 DOI: 10.3389/fmed.2020.592472] [Reference Citation Analysis]
117 Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology 2020;72:431-40. [DOI: 10.1016/j.jhep.2019.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
118 Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
119 Papaluca T, O'Keefe J, Bowden S, Doyle JS, Stoove M, Hellard M, Thompson AJ. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol 2019;120:84-7. [PMID: 31606586 DOI: 10.1016/j.jcv.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
120 Tasillo A, Eftekhari Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R, Randall L, Salomon JA, Linas BP. Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care. Obstet Gynecol 2019;133:289-300. [PMID: 30633134 DOI: 10.1097/AOG.0000000000003062] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
121 Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol 2020;11:710. [PMID: 32508646 DOI: 10.3389/fphar.2020.00710] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
122 Paolucci S, Novazzi F, Piralla A, Maserati R, Gulminetti R, Novati S, Barbarini G, Sacchi P, Fratini A, Bellotti L, Baldanti F. Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. Infect Drug Resist 2019;12:1975-84. [PMID: 31372005 DOI: 10.2147/IDR.S205282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
124 Huff J, Andersen R. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. Ann Pharmacother 2020;54:262-76. [PMID: 31537106 DOI: 10.1177/1060028019877128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
125 Barritt AS, Jhaveri R. Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. Curr HIV/AIDS Rep 2018;15:155-61. [DOI: 10.1007/s11904-018-0386-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
126 Merat SJ, Bru C, van de Berg D, Molenkamp R, Tarr AW, Koekkoek S, Kootstra NA, Prins M, Ball JK, Bakker AQ, de Jong MD, Spits H, Beaumont T, Schinkel J. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. J Hepatol 2019;71:14-24. [PMID: 30797052 DOI: 10.1016/j.jhep.2019.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
127 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
128 Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holten J, Xie F, Druyts E. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. [PMID: 31922124 DOI: 10.1016/j.eclinm.2019.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
129 Gane EJ, Stedman CA, Schwabe C, Vijgen L, Chanda S, Kakuda TN, Fry J, Blatt LM, McClure MW. Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. Hepatology 2018;68:2145-57. [PMID: 30070722 DOI: 10.1002/hep.30126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
130 Kronfli N, Buxton JA, Jennings L, Kouyoumdjian F, Wong A. Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be? CanLivJ 2019;2:171-83. [DOI: 10.3138/canlivj.2019-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
131 Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, Han Q, Lv Y, Liu Z. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. Int J Antimicrob Agents 2019;54:780-9. [PMID: 31284039 DOI: 10.1016/j.ijantimicag.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
132 Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417-426. [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 128] [Article Influence: 28.6] [Reference Citation Analysis]
133 Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:901-10. [PMID: 30058394 DOI: 10.1080/17425255.2018.1506765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
134 Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis 2021;53:612-9. [PMID: 32917546 DOI: 10.1016/j.dld.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
136 Hamed M, El-Hasab M, Mansour FR. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors. Virusdisease 2021;:1-7. [PMID: 33948452 DOI: 10.1007/s13337-021-00691-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infect Dis 2019;19:300. [PMID: 30940090 DOI: 10.1186/s12879-019-3923-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
138 Jhaveri MA, Manne V, Kowdley KV. Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. Drugs Aging 2018;35:117-22. [PMID: 29417462 DOI: 10.1007/s40266-017-0515-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
139 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Microbes Infect 2019;21:263-70. [PMID: 31295571 DOI: 10.1016/j.micinf.2019.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
140 Jhaveri R. Screening for Hepatitis C Virus: How Universal Is Universal? Clin Ther 2020;42:1434-41. [PMID: 32712026 DOI: 10.1016/j.clinthera.2020.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. ACS Med Chem Lett 2018;9:691-6. [PMID: 30034602 DOI: 10.1021/acsmedchemlett.8b00150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
142 Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2018;61:4052-66. [PMID: 29653491 DOI: 10.1021/acs.jmedchem.8b00082] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
143 Levien TL, Baker DE. Formulary Drug Reviews: Glecaprevir/Pibrentasvir. Hosp Pharm 2018;53:75-84. [PMID: 29581598 DOI: 10.1177/0018578717746417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Kinoshita A, Koike K, Mizuno Y, Ogata I, Kobayashi Y, Hasegawa K, Shiraishi K, Yoshida H, Nakata R, Yamada N, Yasuda K. Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years. Geriatr Gerontol Int 2020;20:578-83. [PMID: 32267087 DOI: 10.1111/ggi.13919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatol Res 2019;49:369-76. [PMID: 30485638 DOI: 10.1111/hepr.13292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
146 Zamor PJ, Brown A, Dylla DE, Dillon JF, Luetkemeyer AF, Feld JJ, Mutimer D, Ghalib R, Crown E, Lovell SS, Hu Y, Moreno C, Nelson DR, Colombo M, Papatheodoridis G, Rockstroh JK, Skoien R, Lawitz E, Jacobson IM. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. Am J Gastroenterol 2021;116:1896-904. [PMID: 34465693 DOI: 10.14309/ajg.0000000000001332] [Reference Citation Analysis]
147 Liu X, Hu P. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. J Clin Transl Hepatol 2021;9:125-32. [PMID: 33604263 DOI: 10.14218/JCTH.2020.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
149 Etzion O, Dahari H, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Ashur Y, Uprichard SL, Arbib OS, Munteanu D, Braun M, Cotler SJ, Abufreha N, Keren-Naus A, Shemer-Avni Y, Mor O, Murad J, Novack V, Shlomai A. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Sci Rep 2020;10:17820. [PMID: 33082372 DOI: 10.1038/s41598-020-74568-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
150 . Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr 2018;41:169-70. [PMID: 30410216 DOI: 10.18773/austprescr.2018.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
151 Pawlotsky JM. About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus. J Hepatol 2020;73:752-4. [PMID: 32732060 DOI: 10.1016/j.jhep.2020.06.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther 2021;38:1690-700. [PMID: 33590445 DOI: 10.1007/s12325-021-01647-4] [Reference Citation Analysis]
153 Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 2019;54:291-6. [DOI: 10.1007/s00535-018-1520-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
154 Edmonds C, Carver A, DeClercq J, Choi L, Peter M, Schlendorf K, Perri R, Forbes RC, Concepcion BP. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. Am J Surg 2021:S0002-9610(21)00528-6. [PMID: 34548142 DOI: 10.1016/j.amjsurg.2021.09.005] [Reference Citation Analysis]
155 Saab S, Kullar R, Gounder P. The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action. Obstetrics & Gynecology 2020;135:773-7. [DOI: 10.1097/aog.0000000000003704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
156 Persico M, Aglitti A, Caruso R, Calvanese G, Di Siervi P, Masarone M; the MISTRAL Study Group. Real‐life efficacy and safety of glecaprevir/pibrentasvir in HCV‐infected patients with chronic kidney disease. GastroHep 2019. [DOI: 10.1002/ygh2.351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
157 Parlati L, Hollande C, Pol S. Treatment of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2020;101578. [PMID: 33272891 DOI: 10.1016/j.clinre.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Smith DE, Chen S, Fargnoli A, Lewis T, Galloway AC, Kon ZN, Moazami N. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors. Semin Thorac Cardiovasc Surg 2021;33:407-15. [PMID: 32621962 DOI: 10.1053/j.semtcvs.2020.06.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
159 Said A, Weiss M, Varhelyi A, Farago R, Ballweg C, Rice J, Agarwal P, Fernandez L, Foley D. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. Transpl Infect Dis.  2020: e13466. [PMID: 32931616 DOI: 10.1111/tid.13466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
160 Solomon SS, Quinn TC, Solomon S, McFall AM, Srikrishnan AK, Verma V, Kumar MS, Laeyendecker O, Celentano DD, Iqbal SH, Anand S, Vasudevan CK, Saravanan S, Thomas DL, Sachdeva KS, Lucas GM, Mehta SH. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial. J Hepatol 2020;72:67-74. [PMID: 31604081 DOI: 10.1016/j.jhep.2019.09.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
161 Macken L, Gelson W, Priest M, Abouda G, Barclay S, Fraser A, Healy B, Irving W, Verma S. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. J Med Virol. 2019;91:1979-1988. [PMID: 31329295 DOI: 10.1002/jmv.25552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
162 Feldman TC, Dienstag JL, Mandl KD, Tseng YJ. Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C. Int J Med Inform 2021;154:104562. [PMID: 34482150 DOI: 10.1016/j.ijmedinf.2021.104562] [Reference Citation Analysis]
163 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol 2020;14:579-90. [PMID: 32613874 DOI: 10.1080/17474124.2020.1776111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Ashraf MU, Iman K, Khalid MF, Salman HM, Shafi T, Rafi M, Javaid N, Hussain R, Ahmad F, Shahzad-Ul-Hussan S, Mirza S, Shafiq M, Afzal S, Hamera S, Anwar S, Qazi R, Idrees M, Qureshi SA, Chaudhary SU. Evolution of efficacious pangenotypic hepatitis C virus therapies. Med Res Rev 2019;39:1091-136. [PMID: 30506705 DOI: 10.1002/med.21554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
165 Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol 2020;26:554-61. [PMID: 32854457 DOI: 10.3350/cmh.2020.0058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:855-861. [PMID: 31609495 DOI: 10.1111/jgh.14874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
167 Malov VA, Ubeeva EA, Ubeeva IP, Nikolaev SM, Umbetova KT. [Treatment of chronic viral hepatitis C with direct acting antiviral agent: review]. Ter Arkh 2019;91:86-9. [PMID: 32598617 DOI: 10.26442/00403660.2019.11.000307] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Ohya K, Imamura M, Teraoka Y, Uchida T, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Abe-Chayama H, Hayes CN, Aikata H, Ishida Y, Tateno C, Song H, Miyayama Y, Hijikata M, Chayama K. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. Biochem Biophys Res Commun 2021;559:78-83. [PMID: 33932902 DOI: 10.1016/j.bbrc.2021.04.062] [Reference Citation Analysis]
169 Dvory-Sobol H, Han B, Lu J, Yu M, Beran RK, Cheng G, Martin R, Svarovskaia E, Mo H. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. J Viral Hepat 2019;26:991-1001. [PMID: 31009123 DOI: 10.1111/jvh.13116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
170 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62. [PMID: 29180522 DOI: 10.1128/aac.02217-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
171 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15:412-424. [PMID: 29773899 DOI: 10.1038/s41575-018-0026-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
172 Boonma T, Nutho B, Rungrotmongkol T, Nunthaboot N. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. Comput Biol Chem 2019;83:107154. [PMID: 31751885 DOI: 10.1016/j.compbiolchem.2019.107154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti‐foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort. Liver Int 2020;40:769-77. [DOI: 10.1111/liv.14386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
174 Molinaro S, Resce G, Alberti A, Andreoni M, D′egidio PPF, Leonardi C, Nava FA, Pasqualetti P, Villa S. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. Drug Alcohol Rev 2019;38:644-55. [DOI: 10.1111/dar.12978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
175 Tien A, Sahota A, Yang SJ, Balbuena R, Chang M, Lim C, Fong TL. Prevalence and Characteristics of Chronic Hepatitis C Among Asian Americans Are Distinct From Other Ethnic Groups. J Clin Gastroenterol 2021;55:884-90. [PMID: 33074947 DOI: 10.1097/MCG.0000000000001447] [Reference Citation Analysis]
176 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
177 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology 2021;74:1472-82. [DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
178 Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Nguyen T, Hung Le M, Pham TT, Mensa F, Asselah T. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver Int 2020;40:2385-93. [PMID: 32445613 DOI: 10.1111/liv.14535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
179 Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2019;68:721-8. [PMID: 29666174 DOI: 10.1136/gutjnl-2017-315906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
180 Kosloski MP, Wang H, Pugatch D, Mensa FJ, Gane E, Lawitz E, Marbury TC, Preston RA, Kort J, Liu W. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. Eur J Clin Pharmacol 2019;75:217-26. [PMID: 30341499 DOI: 10.1007/s00228-018-2576-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
181 Shiffman ML. The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver Int 2018;38:34-9. [DOI: 10.1111/liv.13647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
182 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
183 Semenova T, Nemoz B, Thibault V, Lagathu G, Duverlie G, Brochot E, Trimoulet P, Payan C, Vallet S, Henquell C, Chevaliez S, Bouvier-Alias M, Maylin S, Roque-Afonso AM, Izquierdo L, Lunel-Fabiani F, Marcellin P, Morand P, Leroy V, Larrat S. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study. Epidemiol Infect 2019;147:e234. [PMID: 31364570 DOI: 10.1017/S0950268819001225] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Suda G, Hasebe C, Abe M, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Haga H, Ueno Y, Abe K, Takahashi A, Ohira H, Tsukuda Y, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Inoue J, Terasita K, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. J Gastroenterol 2019;54:641-9. [PMID: 30778716 DOI: 10.1007/s00535-019-01556-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
185 Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Biermer M, Vijgen L, Hayashi N. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol 2020;55:640-52. [DOI: 10.1007/s00535-020-01672-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
187 Fadl N, Salem TZ. Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. Rev Med Virol 2020;30:e2120. [PMID: 32478480 DOI: 10.1002/rmv.2120] [Reference Citation Analysis]
188 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
189 Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436-446. [PMID: 31019253 DOI: 10.1038/s41435-019-0066-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
190 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
191 de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. J Antimicrob Chemother 2020;75:3349-58. [PMID: 32772078 DOI: 10.1093/jac/dkaa304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
192 Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, Puoti M, Caruntu F, Slim J, Nevens F, Sigal S, Cohen S, Fredrick LM, Pires Dos Santos AG, Rodrigues L Jr, Dillon JF. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol 2020;18:2544-2553.e6. [PMID: 32621971 DOI: 10.1016/j.cgh.2020.06.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
193 Castellote J, Gea F, Morano LE, Morillas RM, Pineda JA, Vergara M, Buti M. Factors influencing hepatitis C cure in the era of direct-acting antivirals. Gastroenterol Hepatol 2019;42 Suppl 1:1-7. [PMID: 32560767 DOI: 10.1016/S0210-5705(20)30181-3] [Reference Citation Analysis]
194 Liu B, Gai K, Qin H, Wang J, Liu X, Cao Y, Lu Q, Lu D, Chen D, Shen H, Song W, Mei J, Wang X, Xu H, Zhang Y. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor. J Med Chem 2020;63:5312-23. [PMID: 32293179 DOI: 10.1021/acs.jmedchem.0c00082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
195 Steininger L, Chromy D, Bauer D, Simbrunner B, Binter T, Schwabl P, Schmidbauer C, Trauner M, Gschwantler M, Mandorfer M, Reiberger T. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. Wien Klin Wochenschr 2021;133:452-60. [PMID: 33351152 DOI: 10.1007/s00508-020-01790-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Hsu SJ, Chiu MC, Fang YJ, Yang TH, Yu JJ, Chen CC, Kuo CC, Lee JY, Chen CH, Chen DS, Kao JH. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. J Formos Med Assoc 2019;118:1187-92. [PMID: 31279502 DOI: 10.1016/j.jfma.2019.06.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
197 Bushman ET, Subramani L, Sanjanwala A, Dionne-Odom J, Franco R, Owen J, Subramaniam A. Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care. Am J Perinatol 2021;38:1109-16. [PMID: 33934324 DOI: 10.1055/s-0041-1728827] [Reference Citation Analysis]
198 Wei L, Omata M, Lim Y, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han K, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research 2018;158:178-84. [DOI: 10.1016/j.antiviral.2018.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
199 Yeh TK, Kang IJ, Hsu TA, Lee YC, Lee CC, Hsu SJ, Tian YW, Yang HY, Chen CT, Chao YS, Yueh A, Chern JH. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem 2019;167:245-68. [PMID: 30772607 DOI: 10.1016/j.ejmech.2019.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018;41:2-11. [PMID: 29150360 DOI: 10.1016/j.gastrohep.2017.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
201 Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study. J Korean Med Sci 2021;36:e142. [PMID: 34060258 DOI: 10.3346/jkms.2021.36.e142] [Reference Citation Analysis]
202 Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018;67:514-523. [PMID: 28926120 DOI: 10.1002/hep.29541] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 20.8] [Reference Citation Analysis]
203 Rossi RM, Wolfe C, Brokamp R, McAllister JM, Wexelblatt S, Warshak CR, Hall ES. Reported Prevalence of Maternal Hepatitis C Virus Infection in the United States. Obstet Gynecol 2020;135:387-95. [PMID: 31923064 DOI: 10.1097/AOG.0000000000003644] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]